news
Corona
Director General of the Ministry of Health: Agreement to purchase Pfizer's Corona drug - in the coming days
Prof. Ash said that in the coming days Israel will contact the pharmaceutical company in the hope of reaching an agreement for "faxloid" shipments.
"We want to find out more details about the drug's success data," he explained the delay in an interview with 103FM.
The drug is expected to hit the market in the coming months subject to FDA approval
Tags
Corona virus
Pfizer
Nachman Ash
Ministry of Health
Walla!
news
Sunday, 07 November 2021, 08:10 Updated: 08:11
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
In the video: Ministry of Health experts discuss corona vaccine for children (Photo: GPO)
The director general of the Ministry of Health, Prof. Nachman Ash, said this morning (Sunday) that he hopes to reach an agreement in the coming days to purchase the drug for Corona from the pharmaceutical company Pfizer. And not in a hurry as he did in purchasing the vaccines.
"Not yet," he said when asked if Israel had contacted Pfizer. "We will do it in the coming days.
It sounds promising but we need to learn about the success data, side effects, costs. "He explained that unlike the vaccines, the ministry waited for the results of the experiment to be published," and only after that do we make the connection.
I think the good relationship with Pfizer will help us bring the drug quickly. "
More on Walla!
Holocaust survivors who create art?
You really have to know that
To the full article
"I guess the good relationship with Pfizer will help."
Ash (Photo: Flash 90, Avshalom Shashoni)
The Ministry of Health was criticized after Pfizer CEO Albert Burla stated that the company was in negotiations with 90 countries interested in the drug.
However, according to Ash, it is not at all certain that the list does not include Israel.
"We are not in touch at this level that informs us what is going to be published. We knew there was work on such a drug but we did not know what the data was. I do not know what are the 90 countries that contacted us, maybe we are counted in those countries."
He added that "practically we have not yet created an agreement that brings the drug to the country and we will do that, I hope, in the coming days."
He explained the difference between purchasing the vaccines from the drug company.
"Regarding the vaccines, there were many more agreements reached that the vaccines were approved and published. In medicine, a few weeks ago there was a medicine of soup, and now this medicine, and there will be more medicines. We are moving to a different routine of treating this disease."
89% efficacy for Pfizer drug (Photo: Reuters)
The drug has been found to be 89% effective in reducing the risk of hospitalization and death as a result of infection with the virus and the pills are intended for patients who are considered high-risk, adults over 60, immunosuppressed and medically sensitive people such as people with extreme obesity.
The total cost of treatment with the new drug is estimated at about $ 700.
Treatment with the new drug may be available in the coming months, following approval of Pfizer's application to the US Food and Drug Administration (FDA), although supply is likely to be limited at first.
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
